Differences in age at onset, sex, APOE Ɛ4 carrier status, cognitive status, disease duration, and cerebrospinal fluid (CSF) biomarker levels were associated with AD clinical progression and neuropathological staging [1,5]. Here, APOE is linked to Alzheimer disease.